Search

Immunotherapy delivered by Blinatumomab improves survival in acute lymphoblastic leukaemia patients

Adult patients with acute lymphoblastic leukemia (ALL) can achieve disease control in 90% of cases with intense chemotherapy but only half of these responders will be cured.

Read more

Harnessing new developments in genomics to improve outcome for children with poor prognosis leukemia

At the 19th Congress of the European Hematology Association (EHA), we will learn about the state-of-the-art in management of childhood AML.

Read more

EHA-SAH Hematology Tutorial on Acute Leukemia, MDS and BMF

Dates: September 11-12, 2020
Location: Buenos Aires, Argentina
Chairs: G Stemmelin, G Ossenkoppele

The third EHA-SAH Hematology Tutorial will be held in Buenos Aires, Argentina.

Read more

EHA-JSH Travel Grant

Financial support to help EHA members under 40 attend the Japanese Society of Hematology's Annual Meeting in October 2024.

Read more

Restoring Effective Anti-Tumor Response in Hodgkin Lymphoma with Nivolumab

Hodgkin Lymphoma typically affects young men and women in their 30s. Although it is highly curable with the current combination of chemo and radiation therapy, approximately 20% of patients will not be cured with first line regimens.

Read more